Search Within

Gabriella D'Andrea-Carlino

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (5)
Groups
  1. Body Imaging Service (14)
  2. Breast Medicine Service (14)
  3. Department of Medicine (14)
  4. Radiology, Department of (14)
  5. Solid Tumor Oncology Division (14)
  6. Survivorship Research (14)

More Groups

People
  1. Clifford Hudis (13)
  2. Sujata Patil (9)
  3. Diana Lake (8)
  4. Maura Dickler (8)
  5. Larry Norton (7)
  6. Tiffany Traina (7)

More People

Years
  1. 2020 (1)
  2. 2015 (2)
  3. 2014 (1)
  4. 2012 (2)
  5. 2011 (2)
  6. 2010 (2)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer Research (3)
  3. Clinical Breast Cancer (2)
  4. Annals of Oncology (1)
  5. Breast Cancer Research and Treatment (1)
  6. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (4)
  3. Elsevier Inc. (2)
  4. Oxford University Press (1)
  5. Springer (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer
    Meeting Abstract

    Gucalp, A.; Boyle, L. A.; Alano, T.; Arumov, A.; Gounder, M. M.; Patil, S.; Feigin, K.; Edelweiss, M.; D'Andrea, G.; Bromberg, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer
    Meeting Abstract

    Seidman, A. D.; Schwartzberg, L. S.; O'Shaughnessy, J.; D'Andrea, G.; Rubin, P.; Katz, S.; Danesi, H.; Itri, L.; Hudis, C.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Journal Article

    Gajria, D.; Gonzalez, J.; Feigin, K.; Patil, S.; Chen, C.; Theodoulou, M.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; more...
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save
  • TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR-metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Tolaney, S. M.; Isakoff, S. J.; Ingle, J. N.; Liu, M. C.; Carey, L. A.; Blackwell, K. L.; Rugo, H. S.; Nabell, L.; Abbruzzi, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Gajria, D.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; Hudis, C.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    Journal Article

    Conlin, A.; Seidman, A.; Bach, A.; Lake, D.; Dickler, M.; D'Andrea, G.; Traina, T.; Danso, M.; Brufsky, A.; Saleh, M.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save